贝康医疗(02170.HK) 公布，去年度未经审核收入约2.95亿至3.05亿元人民币，按年增长约41.8%至46.6%。
集团指出，收入增加主要由于期内收购新加坡BMX Holdco后借助其覆盖全球的销售网络实现国内自主开发产品的国际销售，推动集团全球销售收入增长；集团成功开发重要的客户关系，例如在北美，集团与Gattaca Genomics订立买卖协议以出售Geri全时差培养箱，在中国集团与上海菁华医疗管理签订战略合作协议以出售涵盖男科检测、胚胎培养，冷藏存储等在内的产品；及集团取得超低温存储仪 — 液氮存储系统(BSG800A、BSG800C)、DA5000高通量基因测序仪和精子品质分析仪(BKA210)的医疗器械注册证书，进一步丰富产品管线，促进产品的市场渗透率和销售增长。(jl/w)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.